Metabolic characterization of colorectal cancer cells harbouring different KRAS mutations in codon 12, 13, 61 and 146 using human SW48 isogenic cell lines

ConclusionsMetabolic differences among differentKRAS mutations might play a role in their different responses to anticancer treatments and hence could be exploited as novel metabolic vulnerabilities to develop more effective therapies against oncogenicKRAS.

http://link.springer.com/10.1007/s11306-020-01674-2

Source: Metabolomics - April 15, 2020 Category: Biology Source Type: research